• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5081853)   Today's Articles (1)
For: Ciccarese C, Iacovelli R, Sternberg CN, Gillessen S, Tortora G, Fizazi K. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. Eur J Cancer 2022;173:276-84. [PMID: 35964470 DOI: 10.1016/j.ejca.2022.07.011] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 07/04/2022] [Accepted: 07/08/2022] [Indexed: 11/21/2022]
Number Cited by Other Article(s)
1
Ibáñez C, Tourís-Lores M, Montesa Á, López-Campos F, Ríos E, Usán P, Moretones C, Conde-Estévez D. Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage. Expert Opin Drug Metab Toxicol 2025;21:625-636. [PMID: 40087028 DOI: 10.1080/17425255.2025.2478167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2024] [Revised: 03/04/2025] [Accepted: 03/07/2025] [Indexed: 03/16/2025]
2
Dodkins J, Cook A, Mayne E, Parry M, Parry MG, Boyle J, Nossiter J, Cowling TE, Tree A, Clarke N, van der Meulen J, Aggarwal A. Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England. Eur J Cancer 2025;220:115335. [PMID: 40056561 DOI: 10.1016/j.ejca.2025.115335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2025] [Revised: 02/18/2025] [Accepted: 02/20/2025] [Indexed: 03/10/2025]
3
Chen W, Yoshida S, Miura N, Fukuda S, Waseda Y, Tanaka H, Fujii Y. Efficacy of docetaxel addition to next-generation androgen receptor-axis-targeted therapies and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: A tumor volume-specific analysis. Int J Urol 2025;32:361-370. [PMID: 39707721 DOI: 10.1111/iju.15657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2024] [Accepted: 12/10/2024] [Indexed: 12/23/2024]
4
Sentana-Lledo D, Chu X, Jarrard DF, Carducci MA, DiPaola RS, Wagner LI, Cella D, Sweeney CJ, Morgans AK. Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED). Eur Urol Oncol 2025;8:29-37. [PMID: 38688766 PMCID: PMC11518880 DOI: 10.1016/j.euo.2024.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2024] [Revised: 03/25/2024] [Accepted: 04/12/2024] [Indexed: 05/02/2024]
5
Ciccarese C, Bauckneht M, Zagaria L, Fornarini G, Beccia V, Lanfranchi F, Perotti G, Pinterpe G, Migliaccio F, Tortora G, Leccisotti L, Sambuceti G, Giordano A, Caffo O, Iacovelli R. Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials. Target Oncol 2025;20:103-112. [PMID: 39613950 DOI: 10.1007/s11523-024-01117-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/13/2024] [Indexed: 12/01/2024]
6
Stroomberg HV, Helgstrand JT, Brasso K, Larsen SB, Røder A. Epidemiology of men with synchronous metastatic prostate cancer diagnosis - A nationwide 26-year temporal analysis. Eur J Cancer 2024;213:115110. [PMID: 39509847 DOI: 10.1016/j.ejca.2024.115110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2024] [Revised: 10/22/2024] [Accepted: 10/25/2024] [Indexed: 11/15/2024]
7
Pedrani M, Salfi G, Merler S, Testi I, Cani M, Turco F, Trevisi E, Tortola L, Treglia G, Di Tanna GL, Vogl U, Gillessen S, Theurillat JP, Pereira Mestre R. Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 2024;7:1199-1215. [PMID: 38704358 DOI: 10.1016/j.euo.2024.04.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2024] [Revised: 03/21/2024] [Accepted: 04/09/2024] [Indexed: 05/06/2024]
8
Borque-Fernando Á, Zapatero A, Manneh R, Alonso-Gordoa T, Couñago F, Domínguez-Esteban M, López-Valcárcel M, Rodríguez-Antolín A, Sala-González N, Sanmamed N, Maroto P. Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection. Actas Urol Esp 2024;48:623-631. [PMID: 38740263 DOI: 10.1016/j.acuroe.2024.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Accepted: 03/07/2024] [Indexed: 05/16/2024]
9
Borque-Fernando Á, Zapatero A, Manneh R, Alonso-Gordoa T, Couñago F, Domínguez-Esteban M, López-Valcárcel M, Rodríguez-Antolín A, Sala-González N, Sanmamed N, Maroto P. Recomendaciones de tratamiento en el cáncer de próstata hormonosensible metastásico: selección de pacientes. Actas Urol Esp 2024;48:623-631. [DOI: 10.1016/j.acuro.2024.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/09/2025]
10
Borque-Fernando A, Pérez-Fentes DA, Rodrigo-Aliaga M, Puente-Vázquez J, Gómez-Iturriaga A, Unda M, Calleja-Hernández MA, Cózar-Olmo JM, Álvarez-Ossorio JL. Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer. Actas Urol Esp 2024:S2173-5786(24)00118-5. [PMID: 39486794 DOI: 10.1016/j.acuroe.2024.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2024] [Revised: 07/18/2024] [Accepted: 07/21/2024] [Indexed: 11/04/2024]
11
Li CX, Li CY, Wang YQ, Liu H, Yang ZJ, Zhang X, Wang GC, Wang L. Sequential versus concomitant treatment of androgen receptor signaling inhibitors and docetaxel for metastatic hormone-sensitive prostate cancer: an network meta-analysis. Front Pharmacol 2024;15:1462360. [PMID: 39529878 PMCID: PMC11551020 DOI: 10.3389/fphar.2024.1462360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2024] [Accepted: 10/15/2024] [Indexed: 11/16/2024]  Open
12
Abu Hijlih R, Sharaf B, Salah S, Bani Hani H, Nielsen SM, Heald B, Esplin ED, Ghanem R, Alzibdeh A, Al-Batsh T, Al-Masri Y, Abdel-Razeq H. Patterns and Frequency of Pathogenic Germline Variants Among Prostate Cancer Patients Utilizing Multi-Gene Panel Genetic Testing. World J Oncol 2024;15:801-808. [PMID: 39328335 PMCID: PMC11424115 DOI: 10.14740/wjon1896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2024] [Accepted: 06/21/2024] [Indexed: 09/28/2024]  Open
13
Bauckneht M, Lanfranchi F, Albano D, Triggiani L, Linguanti F, Urso L, Mazzola R, Rizzo A, D'Angelo E, Dondi F, Mataj E, Pedersoli G, Abenavoli EM, Vaggelli L, Detti B, Ortolan N, Malorgio A, Guarneri A, Garrou F, Fiorini M, Grimaldi S, Ghedini P, Iorio GC, Iudicello A, Rovera G, Fornarini G, Bongiovanni D, Marcenaro M, Pazienza FM, Timon G, Salgarello M, Racca M, Bartolomei M, Panareo S, Ricardi U, Bertagna F, Alongi F, Barra S, Morbelli S, Sambuceti G, Belgioia L. Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study). J Nucl Med 2024;65:1202-1209. [PMID: 38906557 PMCID: PMC11294064 DOI: 10.2967/jnumed.124.267586] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2024] [Accepted: 05/09/2024] [Indexed: 06/23/2024]  Open
14
Gómez-Aparicio MA, López-Campos F, Buchser D, Lazo A, Willisch P, Ocanto A, Sargos P, Shelan M, Couñago F. Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer? Cancers (Basel) 2024;16:2331. [PMID: 39001393 PMCID: PMC11240449 DOI: 10.3390/cancers16132331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2024] [Revised: 06/16/2024] [Accepted: 06/24/2024] [Indexed: 07/16/2024]  Open
15
Grisay G, Lavaud P, Fizazi K. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer. Curr Oncol Rep 2024;26:488-495. [PMID: 38592590 DOI: 10.1007/s11912-024-01509-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/11/2024] [Indexed: 04/10/2024]
16
Pisano C, Turco F, Arnaudo E, Fea E, Vanella P, Ruatta F, Filippi R, Brusa F, Prati V, Vana F, Mennitto A, Cattrini C, Vignani F, Dionisio R, Icardi M, Guglielmini P, Buosi R, Stevani I, Vormola R, Numico G, Depetris I, Comandone A, Gennari A, Airoldi M, Rossi M, Vellani G, Ortega C, Tucci M, Maio MD, Buttigliero C. TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis. Clin Genitourin Cancer 2024;22:56-67.e16. [PMID: 37798164 DOI: 10.1016/j.clgc.2023.08.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2023] [Revised: 08/18/2023] [Accepted: 08/28/2023] [Indexed: 10/07/2023]
17
Sanmamed N, Gómez-Rivas J, Buchser D, Montijano M, Gómez-Aparicio MA, Duque-Santana V, Torres L, Zilli T, Ost P, Maldonado A, López-Campos F, Couñago F. Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd? Clin Genitourin Cancer 2024;22:56-66. [PMID: 37599133 DOI: 10.1016/j.clgc.2023.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 07/25/2023] [Accepted: 08/04/2023] [Indexed: 08/22/2023]
18
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med 2024;30:257-264. [PMID: 38049622 PMCID: PMC10803259 DOI: 10.1038/s41591-023-02704-x] [Citation(s) in RCA: 59] [Impact Index Per Article: 59.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Accepted: 11/10/2023] [Indexed: 12/06/2023]
19
Diaz KA, Amaya SL, García-Perdomo HA. Perspectives on prostate cancer: advances and pending challenges for a multidisciplinary oncological approach in South America. Int Urol Nephrol 2024;56:1-7. [PMID: 37698709 PMCID: PMC10776746 DOI: 10.1007/s11255-023-03753-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Accepted: 08/14/2023] [Indexed: 09/13/2023]
20
Yoo M, Nelson RE, Haaland B, Dougherty M, Cutshall ZA, Kohli R, Beckstead R, Kohli M. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective. J Natl Cancer Inst 2023;115:1374-1382. [PMID: 37436697 PMCID: PMC10637034 DOI: 10.1093/jnci/djad135] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 06/16/2023] [Accepted: 07/06/2023] [Indexed: 07/13/2023]  Open
21
Tsaur I, Mirvald C, Surcel C. Triple therapy in metastatic hormone-sensitive prostate cancer. Curr Opin Urol 2023;33:452-457. [PMID: 37655968 DOI: 10.1097/mou.0000000000001125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
22
Cheret J, Samra T, Verling SD, Gherardini J, Rodriguez-Feliz J, Bauman AJ, Sanchez CA, Wikramanayake TC, Xu XX, Paus R. Low-Intensity Ultrasound as a Potential Intervention Strategy to Protect Human Scalp Hair Follicles from Taxane-Induced Toxicity. J Invest Dermatol 2023;143:1809-1813.e2. [PMID: 36990174 DOI: 10.1016/j.jid.2023.02.033] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 02/09/2023] [Accepted: 02/22/2023] [Indexed: 03/30/2023]
23
Mittal A, Sridhar SS, Ong M, Jiang DM. Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)-A Potential New Standard of Care. Curr Oncol 2023;30:4365-4378. [PMID: 37185445 PMCID: PMC10136811 DOI: 10.3390/curroncol30040332] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 04/17/2023] [Accepted: 04/18/2023] [Indexed: 05/17/2023]  Open
24
Virgo KS, Rumble RB, Talcott J. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol 2023:JCO2300155. [PMID: 37011338 DOI: 10.1200/jco.23.00155] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]  Open
25
Sahu KK, Johnson ED, Butler K, Li H, Boucher KM, Gupta S. Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool. Geriatrics (Basel) 2022;7:133. [PMID: 36547269 PMCID: PMC9778212 DOI: 10.3390/geriatrics7060133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2022] [Revised: 11/06/2022] [Accepted: 11/14/2022] [Indexed: 11/27/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA